Meeting
2023 ASCO Genitourinary Cancers Symposium
Association of baseline inflammatory biomarkers with outcomes in penile squamous cell carcinoma (pSCC) treated with immune checkpoint inhibitors (ICI).
Authors
Tony Zhuang
Department of Medicine, Emory University School of Medicine, Atlanta, GA
Tony Zhuang , Subir Goyal , Jacqueline T Brown , Bradley Curtis Carthon , Omer Kucuk , Greta Russler McClintock , Lauren Beth Yantorni , Mehmet Asim Bilen , Viraj A. Master , Bassel Nazha
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 11)
DOI
10.1200/JCO.2023.41.6_suppl.11
Abstract #
11
Poster Bd #
D16
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study.
First Author: Alessandra Anna Prete
Poster
2023 ASCO Annual Meeting
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
First Author: Tanya Jindal
Poster
2022 ASCO Annual Meeting
Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.
First Author: Joan Miguel Romero
Poster
2022 ASCO Genitourinary Cancers Symposium
FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).
First Author: Elio Adib